Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEM 21S

Drug Profile

GEM 21S

Alternative Names: B-TCP Plus; GEM 21S; GEM21S; GEMESIS

Latest Information Update: 05 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Luitpold Pharmaceuticals
  • Class Growth factors
  • Mechanism of Action Osteogenesis stimulants; Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteonecrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone disorders
  • No development reported Osteonecrosis

Most Recent Events

  • 28 Sep 2018 LYNCH Biologics acquires GEM 21S growth factor enhance matrix from Luitpold Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteonecrosis in USA (Intralesional, Suspension)
  • 20 Mar 2015 No development reported - Registered for Bone disorders in European Union (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top